# Kite Pharma Secures Full FDA Approval for CAR-T Therapy in Mantle Cell Lymphoma

> fda · REPORTED · 2026-04-05

Kite Pharma received full FDA approval for its CAR-T cell therapy for mantle cell lymphoma, converting a prior accelerated approval to full approval based on confirmatory data. The decision marks a significant regulatory milestone for cellular immunotherapy in a rare and aggressive blood cancer.

About Kite Pharma (Gilead Sciences): Kite Pharma, a Gilead Sciences company, develops chimeric antigen receptor T-cell (CAR-T) immunotherapies for hematologic cancers including lymphoma and leukemia.

- Company: Kite Pharma (Gilead Sciences)
- Sector: oncology
- Primary source: https://oncodaily.com/techology/ai479711

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.